C4 Imaging

Executive Summary

C4 Imaging is a private medical device company headquartered in Salt Lake City, Utah, focused on improving the accuracy of cancer treatment through its proprietary non-metallic, MRI-visible fiducial markers. Founded in 2008, the company addresses a critical limitation in radiation oncology: conventional metallic markers cause image distortion and artifacts on MRI, compromising tumor localization and treatment planning. C4's markers are designed to be clearly visible on MRI without significant distortion, enabling precise targeting in radiotherapy, proton therapy, brachytherapy, and image-guided surgery. By enhancing imaging clarity, the technology aims to boost clinician confidence and improve patient outcomes. As a niche player in the radiation oncology market, C4 Imaging benefits from the growing adoption of MRI-guided procedures and the push for more accurate, personalized cancer care. The company's markers offer a clear value proposition over metallic alternatives, potentially reducing planning errors and treatment margins. While the company has not publicly disclosed funding or revenue metrics, its technology addresses a genuine clinical need and could capture share in a market estimated at several hundred million dollars annually. Key risks include competition from other non-metallic markers or advanced imaging techniques, as well the need for regulatory approvals and clinical adoption. Overall, C4 Imaging is well-positioned in a specialized segment with meaningful growth potential, though commercial traction remains unproven.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance for Next-Generation Marker75% success
• TBDPublication of Clinical Study Showing Superiority Over Metallic Markers60% success
• TBDStrategic Partnership with Major Cancer Center or Device OEM40% success